2-Morpholinoethylamine → 6-[2-(2-Morpholin-4-ylethylamino)pyrimidin-4-yl]-2-(2-trimethylsilanyl-ethoxymethyl)-4-[1-(2-trimethylsilanylethoxymethyl)-1H-benzimidazol-2-yl]-2H-pyridazin-3-one

HRID 12288

Reaktionsgleichung

Reaktionsgleichung von HRID 12288
Cl[C:2]1[N:7]=[C:6]([C:8]2[CH:9]=[C:10]([C:23]3[N:27]([CH2:28][O:29][CH2:30][CH2:31][Si:32]([CH3:35])([CH3:34])[CH3:33])[C:26]4[CH:36]=[CH:37][CH:38]=[CH:39][C:25]=4[N:24]=3)[C:11](=[O:22])[N:12]([CH2:14][O:15][CH2:16][CH2:17][Si:18]([CH3:21])([CH3:20])[CH3:19])[N:13]=2)[CH:5]=[CH:4][N:3]=1.[NH2:40][CH2:41][CH2:42][N:43]1[CH2:48][CH2:47][O:46][CH2:45][CH2:44]1>>[N:43]1([CH2:42][CH2:41][NH:40][C:2]2[N:7]=[C:6]([C:8]3[CH:9]=[C:10]([C:23]4[N:27]([CH2:28][O:29][CH2:30][CH2:31][Si:32]([CH3:34])([CH3:33])[CH3:35])[C:26]5[CH:36]=[CH:37][CH:38]=[CH:39][C:25]=5[N:24]=4)[C:11](=[O:22])[N:12]([CH2:14][O:15][CH2:16][CH2:17][Si:18]([CH3:20])([CH3:21])[CH3:19])[N:13]=3)[CH:5]=[CH:4][N:3]=2)[CH2:48][CH2:47][O:46][CH2:45][CH2:44]1

Komponenten

3

Reaktionsbedingungen

Temperatur
100 °C

Versuchsvorschrift

100 mg of 6-(2-chloropyrimidin-4-yl)-2-(2-trimethylsilanylethoxymethyl)-4-[1-(2-trimethylsilanylethoxymethyl)-1H-benzimidazol-2-yl]-2H-pyridazin-3-one are suspended in 0.5 ml of N-(2-aminoethyl)morpholine, and the reaction mixture is heated at 100° C. in a microwave for 20 minutes. The product is purified by preparative RP-HPLC (0-100% acetonitrile (+0.05% formic acid) in water (+0.05% formic acid)).

Aufarbeitung

  1. customThe product is purified by preparative RP-HPLC (0-100% acetonitrile (+0.05% formic acid) in water (+0.05% formic acid))

Quellen und Nachweise

ORD-Eintrag
ord-da03c4138f9d41ce88d2d0a3dba761c6
Quelldatensatz
uspto-grants-2010_06
Patentnummer
US07727989B2

Verknüpfte Notizen

Wird geladen…